Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-10-04, Stock:ABBV, The news for the past five days is as follows:
2019-09-27: NEWS1: AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug.NEWS2: FTC requests AbbVie, Allergan for more information on $63 billion deal.NEWS3: FTC requests AbbVie, Allergan for more information on $63 bln deal.NEWS4: Allergan and AbbVie Receive Second Request from Federal Trade Commission on Pending Transaction.NEWS5: AbbVie and Allergan Receive Second Request from Federal Trade Commission on Pending Transaction.NEWS6: This is Why AbbVie (ABBV) is a Great Dividend Stock.NEWS7: AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes.
2019-09-30: NEWS1: AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know.NEWS2: Healthcare: Political Uncertainties Have Weighed on the Sector.NEWS3: Is AbbVie (ABBV) a Great Value Stock Right Now?.NEWS4: AbbVie (ABBV) Upgraded to Buy: Here's What You Should Know.NEWS5: Here is Why Growth Investors Should Buy AbbVie (ABBV) Now.NEWS6: 5 Most Shorted Sectors in 2019.NEWS7: The 3 Best Health-Care Stocks This Month. And the Worst.
2019-10-01: NEWS1: As Buyout Fever Grows, Alexion, Amarion and BioMarin Are Potential Targets.NEWS2: Top Stock Reports for AbbVie, Starbucks & Phillips 66.NEWS3: AbbVie Falls 3%.NEWS4: AbbVie- The Forest for the Trees.
2019-10-02: NEWS1: Vertex Enters Into Collaboration With Privately-Held Ribometrix.NEWS2: The Zacks Analyst Blog Highlights: AbbVie, Starbucks, Phillips 66, Anheuser-Busch InBev and Square.NEWS3: Top Ranked Income Stocks to Buy for October 2nd.
2019-10-03: NEWS1: Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates.NEWS2: 10 Insider Trading Stocks: What Execs and Directors Are Buying.NEWS3: Novartis Reports Additional Data on Spondylitis Drug Cosentyx.NEWS4: 5 Dividend Aristocrats to Buy as October Sees a Shaky Start.

Answer: Rise